MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

Core Insights - MediciNova, Inc. announced that an abstract regarding the clinical trial of MN-166 (ibudilast) for ALS has been selected for a poster presentation at the 35th International Symposium on ALS/MND in December 2024 [1] - MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines, currently in late-stage clinical development for various neurodegenerative diseases [2] - MediciNova has a broad late-stage pipeline with 11 clinical programs, focusing on inflammatory, fibrotic, and neurodegenerative diseases, with MN-166 being the lead asset [3] Company Overview - MediciNova, Inc. is a clinical-stage biopharmaceutical company developing novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases [3] - The company has two main compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles [3] - MN-166 is currently in Phase 3 trials for ALS and degenerative cervical myelopathy, and is Phase 3-ready for progressive multiple sclerosis [3]